期刊
EUROPEAN JOURNAL OF PHARMACOLOGY
卷 926, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.ejphar.2022.175023
关键词
Gaucher disease; Enzyme replacement therapy; Substrate reduction therapy; Gene therapy; Hematopoietic stem cell transplantation; Genome editing
This paper provides an update on approved therapies and potential curative therapies for Gaucher disease (GD), the most common lysosomal disorder.
Gaucher disease (GD), the most common lysosomal disorders, is a rare autosomal recessive hereditary disease that is caused by deficiency of glucosylceramidase. For now, there are five approved therapies for GD, which are used to treat thousands of patients with GD. Despite success of approved therapies, many unresolved issues attract academic institutions and industry to develop potential therapies to resolve them. This paper updated the latest information about approved therapies and potential curative therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据